Alumis (ALMS) Competitors

$21.88 -0.29 (-1.30%)

As of 03:41 PM Eastern

ALMS vs. AXSM, RDY, ARWR, ELAN, and CYTK

Should you buy Alumis stock or one of its competitors? MarketBeat compares Alumis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alumis include Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.

How does Alumis compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 40.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Alumis had 17 more articles in the media than Axsome Therapeutics. MarketBeat recorded 19 mentions for Alumis and 2 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.55 beat Alumis' score of 0.45 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Alumis has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market.

Axsome Therapeutics presently has a consensus target price of $251.26, suggesting a potential upside of 6.79%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 83.06%. Given Alumis' higher probable upside, analysts plainly believe Alumis is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Axsome Therapeutics has a net margin of -26.59% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Alumis	-2,825.70%	-88.79%	-70.72%

Axsome Therapeutics has higher revenue and earnings than Alumis. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.96	-$183.17M	-$3.73	N/A
Alumis	$24.05M	116.44	-$243.32M	-$1.98	N/A

Summary

Axsome Therapeutics beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Alumis compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, Alumis had 16 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 19 mentions for Alumis and 3 mentions for Dr. Reddy's Laboratories. Alumis' average media sentiment score of 0.45 beat Dr. Reddy's Laboratories' score of 0.07 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories currently has a consensus price target of $16.90, suggesting a potential upside of 24.31%. Alumis has a consensus price target of $40.30, suggesting a potential upside of 83.06%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 40.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.17	$484.20M	$0.58	23.44
Alumis	$24.05M	116.44	-$243.32M	-$1.98	N/A

Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Alumis has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Alumis' net margin of -2,825.70%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%
Alumis	-2,825.70%	-88.79%	-70.72%

Summary

Dr. Reddy's Laboratories beats Alumis on 9 of the 17 factors compared between the two stocks.

How does Alumis compare to Arrowhead Pharmaceuticals?

Alumis (NASDAQ:ALMS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Arrowhead Pharmaceuticals has higher revenue and earnings than Alumis. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	116.44	-$243.32M	-$1.98	N/A
Arrowhead Pharmaceuticals	$622.01M	17.00	-$1.63M	-$2.15	N/A

In the previous week, Alumis had 14 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 19 mentions for Alumis and 5 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.13 beat Alumis' score of 0.45 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis presently has a consensus target price of $40.30, suggesting a potential upside of 83.06%. Arrowhead Pharmaceuticals has a consensus target price of $87.80, suggesting a potential upside of 16.97%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alumis is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Alumis has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 40.7% of Alumis shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Alumis' net margin of -2,825.70%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

Alumis and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Alumis compare to Elanco Animal Health?

Alumis (NASDAQ:ALMS) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Alumis has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

Alumis currently has a consensus target price of $40.30, suggesting a potential upside of 83.06%. Elanco Animal Health has a consensus target price of $28.20, suggesting a potential upside of 29.96%. Given Alumis' stronger consensus rating and higher probable upside, equities analysts plainly believe Alumis is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Elanco Animal Health has higher revenue and earnings than Alumis. Elanco Animal Health is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	116.44	-$243.32M	-$1.98	N/A
Elanco Animal Health	$4.72B	2.30	-$232M	-$0.50	N/A

Elanco Animal Health has a net margin of -4.95% compared to Alumis' net margin of -2,825.70%. Elanco Animal Health's return on equity of 7.42% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Elanco Animal Health	-4.95%	7.42%	3.66%

97.5% of Elanco Animal Health shares are held by institutional investors. 40.7% of Alumis shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alumis had 10 more articles in the media than Elanco Animal Health. MarketBeat recorded 19 mentions for Alumis and 9 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.53 beat Alumis' score of 0.45 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Alumis on 9 of the 15 factors compared between the two stocks.

How does Alumis compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Alumis (NASDAQ:ALMS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Cytokinetics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Alumis has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

Alumis has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	108.63	-$784.96M	-$6.84	N/A
Alumis	$24.05M	116.44	-$243.32M	-$1.98	N/A

Cytokinetics has a net margin of -784.02% compared to Alumis' net margin of -2,825.70%. Cytokinetics' return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Alumis	-2,825.70%	-88.79%	-70.72%

In the previous week, Alumis had 10 more articles in the media than Cytokinetics. MarketBeat recorded 19 mentions for Alumis and 9 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.78 beat Alumis' score of 0.45 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytokinetics presently has a consensus target price of $99.30, suggesting a potential upside of 29.19%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 83.06%. Given Alumis' higher possible upside, analysts clearly believe Alumis is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Cytokinetics beats Alumis on 9 of the 15 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.80B	$3.38B	$6.39B	$12.33B
Dividend Yield	N/A	2.30%	2.79%	5.33%
P/E Ratio	-11.12	19.03	21.06	25.70
Price / Sales	116.44	299.85	580.13	99.36
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	4.94	6.98	10.10	7.04
Net Income	-$243.32M	$24.45M	$3.55B	$335.04M
7 Day Performance	-3.74%	3.76%	4.91%	2.69%
1 Month Performance	-14.97%	-0.17%	1.57%	1.49%
1 Year Performance	354.86%	62.88%	36.63%	35.72%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.517 of 5 stars	$21.88 -1.3%	$40.30 +84.2%	+363.8%	$2.78B	$24.05M	N/A	N/A	Analyst Forecast Analyst Revision
AXSM Axsome Therapeutics	2.632 of 5 stars	$227.72 -2.0%	$251.26 +10.3%	+120.9%	$11.95B	$638.50M	N/A	380
RDY Dr. Reddy's Laboratories	3.4582 of 5 stars	$13.61 +0.9%	$16.90 +24.2%	-5.7%	$11.26B	$3.58B	23.46	27,811
ARWR Arrowhead Pharmaceuticals	2.4959 of 5 stars	$76.67 -3.8%	$87.80 +14.5%	+393.4%	$11.22B	$829.45M	N/A	400	Positive News Analyst Downgrade
ELAN Elanco Animal Health	4.5343 of 5 stars	$19.85 -8.3%	$28.20 +42.0%	+68.6%	$10.81B	$4.72B	N/A	9,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors

ALMS vs. AXSM, RDY, ARWR, ELAN, and CYTK

How does Alumis compare to Axsome Therapeutics?

Summary

How does Alumis compare to Dr. Reddy's Laboratories?

Summary

How does Alumis compare to Arrowhead Pharmaceuticals?

Summary

How does Alumis compare to Elanco Animal Health?

Summary

How does Alumis compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alumis (ALMS) Competitors

ALMS vs. AXSM, RDY, ARWR, ELAN, and CYTK

How does Alumis compare to Axsome Therapeutics?

Do institutionals & insiders believe in AXSM or ALMS?

Does the media refer more to AXSM or ALMS?

Which has more risk and volatility, AXSM or ALMS?

Do analysts rate AXSM or ALMS?

Is AXSM or ALMS more profitable?

Which has preferable valuation & earnings, AXSM or ALMS?

Summary

How does Alumis compare to Dr. Reddy's Laboratories?

Does the media refer more to RDY or ALMS?

Do analysts rate RDY or ALMS?

Do insiders & institutionals believe in RDY or ALMS?

Which has stronger earnings and valuation, RDY or ALMS?

Which has more volatility and risk, RDY or ALMS?

Is RDY or ALMS more profitable?

Summary

How does Alumis compare to Arrowhead Pharmaceuticals?

Which has higher earnings and valuation, ALMS or ARWR?

Does the media prefer ALMS or ARWR?

Do analysts recommend ALMS or ARWR?

Which has more volatility and risk, ALMS or ARWR?

Do insiders and institutionals believe in ALMS or ARWR?

Is ALMS or ARWR more profitable?

Summary

How does Alumis compare to Elanco Animal Health?

Which has more risk & volatility, ALMS or ELAN?

Do analysts recommend ALMS or ELAN?

Which has preferable valuation & earnings, ALMS or ELAN?

Is ALMS or ELAN more profitable?

Do insiders and institutionals believe in ALMS or ELAN?

Does the media prefer ALMS or ELAN?

Summary

How does Alumis compare to Cytokinetics?

Which has more risk and volatility, CYTK or ALMS?

Which has higher earnings & valuation, CYTK or ALMS?

Is CYTK or ALMS more profitable?

Does the media prefer CYTK or ALMS?

Do analysts rate CYTK or ALMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools